Hepatitis C Virus Retreatment Successful with SOF/VEL/VOX in Patients With and Without HIV
November 13th 2018A fixed-dose combination therapy (Vosevi, Gilead) was highly effective after 12 weeks in retreating direct-acting antiviral-experienced patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence.
Addressing Shortcomings in Infection and Sepsis Treatment Should Be Top of the Priority List
November 9th 2018As clinicians and health care executives work to strike a balance between reducing costs and improving clinical outcomes, the importance of sepsis identification and treatment cannot be underscored enough, and starts with evaluating current practices for infection management.